A Safe Start To Bipartisan Pricing Action
This article was originally published in RPM Report
The first “official” Congressional response to the drug pricing debate is a planned hearing in the Senate Special Committee on Aging. While the biopharma industry would prefer other topics of discussion, the forum and focus are about as good as they could be for innovator companies.
Register for our free email digests: